Epidemiology, Demography and Comorbidities of Patients With Osteoporosis at Very High Risk of Fracture in China
Author(s)
wenxuan jiang, master, Pinan Chen, PhD, Shitong Xie, PhD, Jing Wu, PhD.
School of Pharmaceutical Science and Technology, tianjin, China.
School of Pharmaceutical Science and Technology, tianjin, China.
Presentation Documents
OBJECTIVES: Compared to patients with Osteoporosis (OP), those with Osteoporosis at very high risk of fracture (OPVHRF) face worse treatment conditions and bear heavier economic burden. This study aimed to describe the epidemiology, demography and comorbidities of patients with OPVHRF in China.
METHODS: Data were obtained from Tianjin Healthcare Big Data Super Platform (2019-2023). Patients aged ≥50 years with diagnosis of OP during the selection period (June 2020 to June 2021) were identified. The identification criteria for OPVHRF were based on the Guidelines for the Diagnosis and Treatment of Primary Osteoporosis in China (2022). The index date of OPVHRF patients was defined as the first day of OPVHRF diagnosis. The baseline period was defined as 12 months prior to the index date. Patients were followed for at least 2 years until end of the study period, death, or loss to follow-up. The prevalence of hospital visits for OPVHRF among all patients aged ≥50 years with medical records, and the proportion of OPVHRF among OP patients were calculated. Patient characteristics and comorbidities (Charlson Comorbidity Index (CCI) and specific types) were assessed during the baseline period.
RESULTS: Out of 3,192,119 patients in selection period from database, 71,792 OP patients were identified, among whom 19,993 were diagnosed with OPVHRF. This corresponded to annual prevalence of hospital visits for OPVHRF of 0.63% and proportion of OPVHRF of 27.85%. The mean (SD) age of OPVHRF patients was 65.9 (10.0) years, and 58.39% were female. The mean (SD) CCI of OPVHRF patients was 0.57 (1.02). The cardio- and cerebrovascular diseases were common comorbidities among patients with OPVHRF including hypertension (28.52%), stroke (10.40%) and arrhythmia (7.23%).
CONCLUSIONS: Almost one third of OP patients were identified as OPVHRF in China, with an advanced mean age and comorbidities primarily concentrated in cardio- and cerebrovascular diseases. These patients require increased attention and targeted management.
METHODS: Data were obtained from Tianjin Healthcare Big Data Super Platform (2019-2023). Patients aged ≥50 years with diagnosis of OP during the selection period (June 2020 to June 2021) were identified. The identification criteria for OPVHRF were based on the Guidelines for the Diagnosis and Treatment of Primary Osteoporosis in China (2022). The index date of OPVHRF patients was defined as the first day of OPVHRF diagnosis. The baseline period was defined as 12 months prior to the index date. Patients were followed for at least 2 years until end of the study period, death, or loss to follow-up. The prevalence of hospital visits for OPVHRF among all patients aged ≥50 years with medical records, and the proportion of OPVHRF among OP patients were calculated. Patient characteristics and comorbidities (Charlson Comorbidity Index (CCI) and specific types) were assessed during the baseline period.
RESULTS: Out of 3,192,119 patients in selection period from database, 71,792 OP patients were identified, among whom 19,993 were diagnosed with OPVHRF. This corresponded to annual prevalence of hospital visits for OPVHRF of 0.63% and proportion of OPVHRF of 27.85%. The mean (SD) age of OPVHRF patients was 65.9 (10.0) years, and 58.39% were female. The mean (SD) CCI of OPVHRF patients was 0.57 (1.02). The cardio- and cerebrovascular diseases were common comorbidities among patients with OPVHRF including hypertension (28.52%), stroke (10.40%) and arrhythmia (7.23%).
CONCLUSIONS: Almost one third of OP patients were identified as OPVHRF in China, with an advanced mean age and comorbidities primarily concentrated in cardio- and cerebrovascular diseases. These patients require increased attention and targeted management.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD101
Topic
Real World Data & Information Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)